title: A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients?
authors.forename: Daniel F
authors.initials: DF
authors.lastname: Hayes
authors.forename: Vered
authors.initials: V
authors.lastname: Stearns
authors.forename: James
authors.initials: J
authors.lastname: Rae
authors.forename: David
authors.initials: D
authors.lastname: Flockhart
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics*; D065690:Cytochrome P-450 CYP2D6 Inhibitors; D005260:Female; D006801:Humans; D008875:Middle Aged; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy / Q000235:genetics; D017698:Postmenopause; D011960:Receptors, Estrogen / Q000032:analysis; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*; D013629:Tamoxifen / Q000627:therapeutic use*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D065690:Cytochrome P-450 CYP2D6 Inhibitors; D011960:Receptors, Estrogen; D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen; D019389:Cytochrome P-450 CYP2D6